Rain oncology co-founders Robert Doebele (L) and Avanish Vellanki
After PhIII letdown, Rain Oncology lays off 65% of staff, alters clinical plans for sole asset
Rain Oncology will let go 65% of its workers, stop enrolling patients in a basket trial and nix plans for another study of its sole …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
